Multidrug-resistant tuberculosis in Uzbekistan: Results of a nationwide survey, 2010 to 2011

Eurosurveillance

Volumn 18, Issue 42, 2013, Pages

  Ulmasova, D J ^a   Uzakova, G ^b   Tillyashayhov, M N ^c   Turaev, L ^d   van Gemert, W ^e   Hoffmann, H ^f   Zignol, M ^e   Kremer, K ^e   Gombogaram, T ^e   Gadoev, J ^e   du Cros, P ^g   Muslimova, N ^d   Jalolov, A ^b   Dadu, A ^e   de Colombani, P ^a   Telnov, O ^g   Slizkiy, A ^g   Kholikulov, B ^a   Dara, M ^e   Falzon, D ^e  

^a DOTS Center   (Uzbekistan)

^b TB and Malaria   (Uzbekistan)

^c National Institute of TB and Pulmonology   (Uzbekistan)

^d National Reference Laboratory   (Uzbekistan)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEALTH SURVEY; HUMAN; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; RISK FACTOR; UZBEKISTAN;

EID: 84886883603     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2013.18.42.20609     Document Type: Article

References (34)

1. World Health Organization (WHO). Global Tuberculosis Report 2012. Geneva: WHO; 2012. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf
2. World Health Organization (WHO). Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: WHO; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241501330_eng.pdf
3. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516-28. http://dx.doi.org/10.1183/09031936.00073611. PMid:21828024.
4. World Health Organization (WHO). Treatment of tuberculosis: guidelines. 4th ed. Geneva: WHO; 2009. Available from: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf
5. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf
6. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ. 2013;91(1):36-45. http://dx.doi.org/10.2471/BLT.12.104588. PMid:23397349. PMCid:PMC3537245.
7. Cox HS, Orozco JD, Male R, Ruesch-Gerdes S, Falzon D, Small I, et al. Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis. 2004;10(5):865-72. http://dx.doi.org/10.3201/eid1005.030718. PMid:15200821. PMCid:PMC3323206.
8. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world. Report No. 4. Geneva: WHO; 2008. Available from: http://whqlibdoc.who.int/hq/2008/who_htm_tb_2008.394_eng.pdf
9. The World Bank. Uzbekistan. Washington: The World Bank. [Accessed 18 Jun 2013]. Available from: data.worldbank.org/country/uzbekistan
10. European Centre for Disease Prevention and Control (ECDC) / World Health Organization (WHO) Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: ECDC; 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/Tuberculosis-surveillance-monitoring-2013.pdf
11. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012;90(2):111-119D. http://dx.doi.org/10.2471/BLT.11.092585. PMid:22423162. PMCid:PMC3302554.
12. Falzon D, Infuso A, Aït-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis. 2006;10(9):954-8. PMid:16964783.
13. World Health Organization (WHO). WHO Global Task Force outlines measures to combat XDR-TB worldwide. Geneva: WHO; 17 Oct 2006. Available from: www.who.int/mediacentre/news/notes/2006/np29/en/
14. World Health Organization (WHO). Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. Geneva: WHO; 2009. Available from: http://whqlibdoc.who.int/publications/2009/9789241598675_eng.pdf
15. The R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. Available from: http://cran.r-project.org/
16. World Health Organization (WHO). Seventh meeting of the Strategic and Technical Advisory Group for Tuberculosis (STAG-TB). Report on conclusions and recommendations. Geneva: WHO; 2007. Available from: http://www.who.int/tb/events/stag_report_2007.pdf
17. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969;41(1):21-43. PMid:5309084. PMCid:PMC2427409.
18. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J. 2013;42(1):156-68. http://dx.doi.org/10.1183/09031936.00134712. PMid:23100499.
19. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis, Emergency update 2008. Geneva: WHO; 2008. Available from: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf
20. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis. 1999;3(5):451-3. PMid:10331736.
21. Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One. 2007;2(11):e1126. http://dx.doi.org/10.1371/journal.pone.0001126. PMid:17987113. PMCid:PMC2040509.
22. Lalor M, Allamuratova S, Tiegay Y, Khamraev A, Greig J, Braker K, et al. Treatment outcomes in multidrug-resistant TB patients in Uzbekistan (Poster). 42nd Union World Conference on Lung Health. Lille, France; 2011.
23. Gilpin C, de Colombani P, Hasanova S, Sirodjiddinova U. Exploring TB-Related Knowledge, Attitude, Behaviour, and Practice among Migrant Workers in Tajikistan. Tuberc Res Treat. 2011: 548617. PMid:22567266. PMCid:PMC3335497.
24. Huffman SA, Veen J, Hennink MM, McFarland DA. Exploitation, vulnerability to tuberculosis and access to treatment among Uzbek labor migrants in Kazakhstan. Soc Sci Med. 2012;74(6):864-72. http://dx.doi.org/10.1016/j.socscimed.2011.07.019. PMid:22094009.
25. Herm A. Population and social conditions. Statistics in Focus. 98/2008. Luxembourg: Eurostat Available from: http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-SF-08-098/EN/KS-SF-08-098-EN.pdf
26. Bernard C, Brossier F, Sougakoff W, Veziris N, Frechet-Jachym M, Metivier N, et al. A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Euro Surveill. 2013;18(33):pii=20555. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20555. PMid:23968874.
27. Fleming MF, Krupitsky E, Tsoy M, Zvartau E, Brazhenko N, Jakubowiak W, et al. Alcohol and drug use disorders, HIV status and drug resistance in a sample of Russian TB patients. Int J Tuberc Lung Dis. 2006;10(5):565-70. PMid:16704041. PMCid:PMC1570181.
28. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Jibuti T, Shubladze N, et al. High Prevalence of Multidrug-Resistant Tuberculosis in Georgia. Int J Infect Dis. 2008;12(6):635-44. http://dx.doi.org/10.1016/j.ijid.2008.03.012. PMid:18514008. PMCid:PMC2645041.
29. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300. PMid:22952439. PMCid:PMC3429397.
30. World Health Organization (WHO). Resolution WHA62. 15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. In: Sixty-second World Health Assembly, Geneva, 18-22 May 2009, Resolutions and decisions; annexes. Geneva: WHO; 2009. Available from: apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf
31. World Health Organization (WHO). Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. Geneva: WHO; 2011. Available from: apps.who.int/medicinedocs/documents/s19053en/s19053en.pdf
32. World Health Organization (WHO) Regional Office for Europe. Roadmap to prevent and combat drug-resistant tuberculosis. The Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011-2015. Copenhagen: WHO; 2011. Available from: www.euro.who.int/__data/assets/pdf_file/0014/152015/e95786.pdf
33. World Health Organization (WHO). Rapid Implementation of the Xpert MTB/RIF diagnostic test. Technical and operational "How-to" Practical considerations. Geneva: WHO. 2011; Available from: whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf
34. Royce S, Falzon D, van Weezenbeek C, Dara M, Hyder K, Hopewell P, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis. 2013;17(4):511-3. http://dx.doi.org/10.5588/ijtld.12.0286. PMid:23485384.